TNSN98158A1 - Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation - Google Patents
Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparationInfo
- Publication number
- TNSN98158A1 TNSN98158A1 TNTNSN98158A TNSN98158A TNSN98158A1 TN SN98158 A1 TNSN98158 A1 TN SN98158A1 TN TNSN98158 A TNTNSN98158 A TN TNSN98158A TN SN98158 A TNSN98158 A TN SN98158A TN SN98158 A1 TNSN98158 A1 TN SN98158A1
- Authority
- TN
- Tunisia
- Prior art keywords
- amlodipine
- preparation
- statin
- pharmaceutical combinations
- treatment
- Prior art date
Links
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000528 amlodipine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
Abstract
L'INVENTION CONCERNE DES ASSOCIATIONS PHARMACEUTIQUES D'AMLODIPINE OU D'UN DES SES SELS D'ADDITION D'ACIDE PHARMACEUTIQUEMENT ACCEPTABLES ET D'UNE STATINE OU DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LA PREPARATION D'ASSOCIATIONS DE COMPOSITIONS PHARMACEUTIQUES AINSI QUE DES KITS CONTENANT CELLES-CI. APPLICATION : UTILISATION POUR LE TRAITEMENT DE SUJETS SOUFFRANT D'ANGINE DE POITRINE, D'ATHEROSCLEROSE, D'HYPERTENSION ET D'HYPERLIPIDEMIE EN ASSOCIATION, ET POUR LE TRAITEMENT DE SUJETS PRESENTANT DES SYMPTOMES DE RISQUES CARDIAQUES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5755597P | 1997-08-29 | 1997-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN98158A1 true TNSN98158A1 (fr) | 2005-03-15 |
Family
ID=22011309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN98158A TNSN98158A1 (fr) | 1997-08-29 | 1998-08-26 | Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20020025981A1 (fr) |
| EP (1) | EP1003507A1 (fr) |
| JP (1) | JP2001514224A (fr) |
| KR (1) | KR20010022385A (fr) |
| CN (1) | CN1117566C (fr) |
| AP (1) | AP1207A (fr) |
| AR (1) | AR017514A1 (fr) |
| AU (1) | AU744982B2 (fr) |
| BG (1) | BG104076A (fr) |
| BR (1) | BR9811558A (fr) |
| CA (1) | CA2296726C (fr) |
| CO (1) | CO4970726A1 (fr) |
| DZ (1) | DZ2600A1 (fr) |
| EA (1) | EA002705B1 (fr) |
| GT (1) | GT199800134A (fr) |
| HN (1) | HN1998000124A (fr) |
| HR (1) | HRP980475A2 (fr) |
| HU (1) | HUP0003103A3 (fr) |
| ID (1) | ID24275A (fr) |
| IL (2) | IL133957A0 (fr) |
| IS (1) | IS5345A (fr) |
| MA (1) | MA26539A1 (fr) |
| NO (1) | NO20000999L (fr) |
| NZ (1) | NZ502283A (fr) |
| OA (1) | OA11289A (fr) |
| PA (1) | PA8457201A1 (fr) |
| PE (1) | PE106999A1 (fr) |
| PL (1) | PL339088A1 (fr) |
| SA (1) | SA98190432A (fr) |
| SK (1) | SK1392000A3 (fr) |
| TN (1) | TNSN98158A1 (fr) |
| TR (1) | TR200000562T2 (fr) |
| UY (1) | UY25159A1 (fr) |
| WO (1) | WO1999011263A1 (fr) |
| YU (1) | YU2700A (fr) |
| ZA (1) | ZA987843B (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993023069A1 (fr) | 1992-05-19 | 1993-11-25 | Graham Edmund Kelly | Complements benefiques pour la sante, contenant des phyto-×strogenes, des analogues ou des metabolites de ceux-ci |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| WO2000038721A1 (fr) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires |
| EP1076091A1 (fr) * | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Composé ou composition pharmaceutique pour la prévention et/ou le traitement d'ischémie cardiaque, de maladies vasculaires périphériques, de tumeurs et de plaies |
| AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| AU2001284413A1 (en) * | 2000-08-30 | 2002-03-13 | Sankyo Company Limited | Medicinal compositions for preventing or treating heart failure |
| AUPR255401A0 (en) * | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
| AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
| US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
| WO2003061604A2 (fr) | 2002-01-17 | 2003-07-31 | Pharmacia Corporation | Nouveaux composes d'alkyl/aryl hydroxy ou cetothiepine servant d'inhibiteurs du transport des acides biliaires de type ileal et de l'absorption de taurocholate |
| NL1019882C2 (nl) * | 2002-02-01 | 2003-08-04 | Synthon Licensing | Amlodipine vrije base. |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2005097191A2 (fr) * | 2004-04-04 | 2005-10-20 | Sepracor Inc. | Combinaisons comprenant de la (s)-amlodipine et un inhibiteur de la hmg-coa reductase ou un inhibiteur de l'absorption de cholesterol ou les deux a la fois et methodes permettant de reduire l'hypertension |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| KR100742432B1 (ko) | 2005-12-27 | 2007-07-24 | 한미약품 주식회사 | 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법 |
| CN101415425B (zh) | 2006-03-29 | 2014-11-26 | 兴和株式会社 | 甘油三酯降低剂和高胰岛素血症改善剂 |
| WO2008023869A1 (fr) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | PRÉPARATION PHARMACEUTIQUE COMBINÉE À LIBÉRATION CONTRÔLÉE COMPRENANT DES INHIBITEURS CALCIQUES À BASE DE DIHYDROPYRIDINE ET DES INHIBITEURS DE HMG-CoA RÉDUCTASE |
| WO2008023958A1 (fr) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Composition pharmaceutique combinée à libération contrôlée comprenant de la dihydropyridine, des bloqueurs de canal calcium et des inhibiteurs de l'hgm-coa réductase |
| MX2007008440A (es) * | 2007-07-11 | 2009-02-18 | Senosiain S A De C V Lab | Composicion farmaceutica combinada. |
| KR101207618B1 (ko) * | 2008-02-22 | 2012-12-04 | 한올바이오파마주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
| WO2009125987A2 (fr) * | 2008-04-10 | 2009-10-15 | 한올제약주식회사 | Préparation pharmaceutique |
| WO2010008203A2 (fr) * | 2008-07-15 | 2010-01-21 | 한올제약주식회사 | Preparation pharmaceutique contenant un inhibiteur des canaux calciques |
| CN101804055B (zh) * | 2010-04-27 | 2012-01-25 | 施慧达药业集团(吉林)有限公司 | 复方药物制剂 |
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| EP3253382B1 (fr) | 2015-02-06 | 2021-11-17 | Intercept Pharmaceuticals, Inc. | Compositions pharmaceutiques pour thérapie combinée |
| WO2019094581A1 (fr) * | 2017-11-10 | 2019-05-16 | Op-T Llc | Procédés de prévention, de modulation et/ou de réduction d'une maladie cardiovasculaire |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| US12377045B2 (en) | 2019-11-25 | 2025-08-05 | Fordoz Pharma Corp. | Oral liquid formulations of lipid-lowering and blood pressure-lowering drugs |
| EP4135742A2 (fr) | 2020-04-17 | 2023-02-22 | Op-T Llc | Peptides bioactifs et leurs méthodes d'utilisation |
| CN112826937B (zh) * | 2021-03-25 | 2022-03-22 | 山东大学齐鲁医院 | 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN176897B (fr) * | 1993-10-29 | 1996-09-28 | Cadila Lab Ltd | |
| DE19539363A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
-
1998
- 1998-08-10 JP JP2000508366A patent/JP2001514224A/ja active Pending
- 1998-08-10 HU HU0003103A patent/HUP0003103A3/hu unknown
- 1998-08-10 HN HN1998000124A patent/HN1998000124A/es unknown
- 1998-08-10 IL IL13395798A patent/IL133957A0/xx unknown
- 1998-08-10 BR BR9811558-8A patent/BR9811558A/pt not_active Application Discontinuation
- 1998-08-10 PL PL98339088A patent/PL339088A1/xx unknown
- 1998-08-10 SK SK139-2000A patent/SK1392000A3/sk unknown
- 1998-08-10 EP EP98935246A patent/EP1003507A1/fr not_active Withdrawn
- 1998-08-10 AU AU84585/98A patent/AU744982B2/en not_active Ceased
- 1998-08-10 KR KR1020007000964A patent/KR20010022385A/ko not_active Ceased
- 1998-08-10 ID IDW20000199A patent/ID24275A/id unknown
- 1998-08-10 NZ NZ502283A patent/NZ502283A/en unknown
- 1998-08-10 CA CA002296726A patent/CA2296726C/fr not_active Expired - Fee Related
- 1998-08-10 WO PCT/IB1998/001220 patent/WO1999011263A1/fr not_active Ceased
- 1998-08-10 TR TR2000/00562T patent/TR200000562T2/xx unknown
- 1998-08-10 CN CN98808465A patent/CN1117566C/zh not_active Expired - Fee Related
- 1998-08-10 AP APAP/P/1998/001333A patent/AP1207A/en active
- 1998-08-10 YU YU2700A patent/YU2700A/sh unknown
- 1998-08-10 EA EA200000013A patent/EA002705B1/ru not_active IP Right Cessation
- 1998-08-11 PA PA19988457201A patent/PA8457201A1/es unknown
- 1998-08-17 GT GT199800134A patent/GT199800134A/es unknown
- 1998-08-19 SA SA98190432A patent/SA98190432A/ar unknown
- 1998-08-24 PE PE1998000768A patent/PE106999A1/es not_active Application Discontinuation
- 1998-08-26 MA MA25231A patent/MA26539A1/fr unknown
- 1998-08-26 DZ DZ980210A patent/DZ2600A1/fr active
- 1998-08-26 TN TNTNSN98158A patent/TNSN98158A1/fr unknown
- 1998-08-27 AR ARP980104289A patent/AR017514A1/es unknown
- 1998-08-27 UY UY25159A patent/UY25159A1/es not_active Application Discontinuation
- 1998-08-27 CO CO98049137A patent/CO4970726A1/es unknown
- 1998-08-28 ZA ZA9807843A patent/ZA987843B/xx unknown
- 1998-08-28 HR HR60/057,555A patent/HRP980475A2/hr not_active Application Discontinuation
-
2000
- 2000-01-09 IL IL133957A patent/IL133957A/en unknown
- 2000-01-13 BG BG104076A patent/BG104076A/xx unknown
- 2000-01-14 IS IS5345A patent/IS5345A/is unknown
- 2000-02-18 OA OA1200000038A patent/OA11289A/en unknown
- 2000-02-28 NO NO20000999A patent/NO20000999L/no not_active Application Discontinuation
-
2001
- 2001-10-10 US US09/975,765 patent/US20020025981A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN98158A1 (fr) | Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation | |
| TNSN98156A1 (fr) | Associations pharmaceutiques d'amlodipine et d'atorvastatine et procede pour leur preparation | |
| TNSN98155A1 (fr) | Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation | |
| TNSN01125A1 (fr) | Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine | |
| MA26739A1 (fr) | Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant | |
| CA2191129A1 (fr) | Medicaments a base de metronidazole ou d'un melange synergetique de metronidazole et de clindamycine | |
| TNSN04022A1 (fr) | Compositions pharmaceutiques d'amlodipine et d'atorvastatine | |
| TNSN97193A1 (fr) | Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN98025A1 (fr) | Derives d'acide arylsulfonylhydroxamique, procede pour leur preparation et compositions les contenant. | |
| TNSN99006A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| CA2206837A1 (fr) | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose | |
| TNSN98140A1 (fr) | Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2708605A1 (fr) | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. | |
| TNSN00113A1 (fr) | Precurseurs medicamenteux mutuels d'amlodipine et d'atorvastatine, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN96104A1 (fr) | Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant | |
| TNSN98127A1 (fr) | Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN99013A1 (fr) | Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA24704A1 (fr) | Formulations nouvelles de paroxetine et procede pour leur preparation | |
| MA24682A1 (fr) | Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant | |
| TNSN00142A1 (fr) | Complexe d'eletriptan et d'une sulfobutylether- betacyclodextrine, procede pour sa preparation et compositions pharmaceutiques les contenant. | |
| TNSN97042A1 (fr) | Derives de quinoxaline utiles en therapeutique, procede pour leur preparation et formulations pharmaceutiques les contenant. | |
| TNSN98033A1 (fr) | Derives de quinoxalinedione, procede pour leur preparation et compositions pharmaceutiques les contenant. |